CDK5 and medullary thyroid gland carcinoma: Given the role of Cdk5 in MTC proliferation [16] and in angiogenesis [37], Cdk5 inhibitors might be considered as therapeutic drugs to be used alone or in combination with a TKI such as Nintedanib.